Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Duda

Showing results (241-250 of 338) with videos related to

Pageof 34
Sort By:
Neuro-Oncology Advances|January 4, 2021
Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patientsElizabeth R Gerstner, Kyrre E Emblem, Yi-Fen Yen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancerAndrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Cancer|February 14, 2017
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinomaLipika Goyal, Hui Zheng, Matthew B Yurgelun, et al.
Cancer|December 22, 2017
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastomaDavid A Reardon, Andrew B Lassman, David Schiff, et al.
The Oncologist|July 30, 2010
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancerChristopher G Willett, Dan G Duda, Marek Ancukiewicz, et al.
Hepatology (Baltimore, Md.)|August 6, 2019
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular CarcinomaKohei Shigeta, Meenal Datta, Tai Hato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2024
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast CancerAlice Y Ho, Stephen Shiao, Samantha A Kobald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar RhabdomyosarcomaGiselle Saulnier-Sholler, Dan G Duda, Genevieve Bergendahl, et al.
Molecular Therapy Oncolytics|August 26, 2020
Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic CancersBolni Marius Nagalo, Camilo Ayala Breton, Yumei Zhou, et al.
Pageof 34

Showing results (241-250 of 338) with videos related to

Sort By:
Pageof 34
Neuro-Oncology Advances|January 4, 2021
Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patientsElizabeth R Gerstner, Kyrre E Emblem, Yi-Fen Yen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancerAndrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Cancer|February 14, 2017
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinomaLipika Goyal, Hui Zheng, Matthew B Yurgelun, et al.
Cancer|December 22, 2017
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastomaDavid A Reardon, Andrew B Lassman, David Schiff, et al.
The Oncologist|July 30, 2010
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancerChristopher G Willett, Dan G Duda, Marek Ancukiewicz, et al.
Hepatology (Baltimore, Md.)|August 6, 2019
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular CarcinomaKohei Shigeta, Meenal Datta, Tai Hato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2024
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast CancerAlice Y Ho, Stephen Shiao, Samantha A Kobald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar RhabdomyosarcomaGiselle Saulnier-Sholler, Dan G Duda, Genevieve Bergendahl, et al.
Molecular Therapy Oncolytics|August 26, 2020
Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic CancersBolni Marius Nagalo, Camilo Ayala Breton, Yumei Zhou, et al.
Pageof 34